Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis

Background Prolonged-release (PR) fampridine is a potassium channel blocker used as a symptomatic treatment for walking disability in patients with multiple sclerosis (MS). Its clinical effects in such patients have not been systematically reviewed, and may be more wide-ranging than expected.